Blueprint Medicines (BPMC) Misses Q2 EPS by 13c, Revenues Beat

August 1, 2019 7:23 AM

Blueprint Medicines (NASDAQ: BPMC) reported Q2 EPS of ($2.04), $0.13 worse than the analyst estimate of ($1.91). Revenue for the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found